ATRA

Atara Biotherapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$7.93

Price (1 Year)

$18 $4.18

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.1 / %30
Non-compliant assets / Total market cap %8.6 / %30
Non-compliant revenue / Total income %10.3 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.

Website

Analysis (Turkish): ATRA Hissesi Caiz mi, Helal mi? Atara Biotherapeutics, Inc. Katılım Analizi